Fox Chase Cancer Center News

Using the first-ever prostate cancer cell line from an Afro-Caribbean patient, investigators at Fox Chase Cancer Center and other members of the African Caribbean Cancer Consortium uncovered significant differences in how cancer drugs work across ancestries. These differences may help explain why, despite advances in treatment, Black men die from prostate cancer at twice the rate of White men.

For more than a decade, a class of drugs called spliceosome inhibitors has been studied as a strategy for killing cancer cells. Now, new research by Fox Chase Cancer Center scientists suggests that these drugs may be more effective as a tool to supercharge immunotherapy, drugs that harness the power of the body’s immune system, in small cell lung cancer.

Fox Chase Cancer Center’s Namrata ‘Neena’ Vijayvergia, MD, an expert in gastrointestinal cancers and rare neuroendocrine tumors, was recently recognized by two neuroendocrine tumor advocacy groups for her contributions to the field.

Researchers at Fox Chase Cancer Center, Temple University’s College of Engineering, and the Lewis Katz School of Medicine at Temple University have developed a new method that enhances the ability of artificial intelligence models to detect and diagnose skin cancer in individuals with darker skin.

Researchers at Fox Chase Cancer Center have uncovered a new mechanism by which the body’s immune system responds to viral infections, a finding that can potentially be harnessed to attack cancer.

Robert Uzzo, MD, MBA’s role as President & CEO of Fox Chase Cancer Center will now extend beyond the American Oncologic Hospital and include the Institute for Cancer Research, uniting Fox Chase’s dual missions of cancer care and research.

When cancer strikes young, the future feels uncertain, especially for those hoping to start a family. Fox Chase Cancer Center’s new Young Adult Cancer Program is tackling that head-on, making fertility preservation a priority and offering hope to patients.

Researchers at Fox Chase Cancer Center have demonstrated that pulsed low dose rate (PLDR) chemoradiation therapy can significantly reduce side effects while maintaining treatment effectiveness for patients with esophageal cancer and non-small cell lung cancer.